低分子肝素治疗新生儿败血症的效果(1)
[摘要]目的 探讨低分子肝素治疗新生儿败血症的有效性。方法 收集2015年3月～2016年7月我院58例新生儿败血症患儿，按照入院顺序分成观察组与对照组，每组29例，对照组患儿实施传统抗生素类药物治疗，观察组患儿在对照组的基础上予以低分子肝素治疗，对比两组患儿临床治疗效果及治疗前后降钙素原(PCT)、C反应蛋白(CRP)水平变化。结果 观察组患儿总有效率为96.55%，高于对照组的86.21%，差异有统计学意义(P<0.05)。观察组治疗后PCT和CRP为(0.29±0.17)ng/L和(5.52±2.37)mg/L，明显低于治疗前的(5.65±2.18)ng/L和(22.70±5.29)mg/L(P<0.05)；观察组治疗后PCT、CRP明显低于对照组，差异有统计学意义(P<0.05)。结论 低分子肝素联合抗生素治疗新生儿败血症具有明显的臨床效果，可明显改善PCT、CRP，临床应用价值较高。
[关键词]低分子肝素；新生儿败血症；降钙素原；C反应蛋白
[中图分类号] R722.13+1 [文献标识码] A [文章编号] 1674-4721(2017)01(c)-0098-03
[Abstract]Objective To investigate effectiveness of low molecular heparin in the treatment of neonatal sepsis.Methods 58 cases of neonatal septicemia in our hospital from March 2015 to July 2016 were collected and divided into observation group and control group according to admission order，29 cases in each group.Patients in the control group were treated by traditional antibiotic treatment，patients in the observation group were treated with low molecular heparin on the basis of the control group，clinical therapeutic effect，changes of procalcitonin (PCT) and C reactive protein (CRP) levels before and after treatment between two groups were compared.Results Total effective rate in the observation group was 96.55%，higher than 86.21% in the control group，and the difference was statistically significant (P<0.05).PCT and CRP level after treatment in the observation group was (0.29±0.17) ng/L and (5.52±2.37) mg/L respectively，significantly lower than (5.65±2.18) ng/L and (22.70±5.29 mg/L before treatment (P<0.05)；PCT and CRP level after treatment in the observation group was significantly lower than that in the control group，and the difference was statistically significant (P<0.05).Conclusion Low molecular heparin combined antibiotics in the treatment of neonatal sepsis has obvious clinical effect，can significantly improve procalcitonin and CRP level，which has high clinical value.
[Key words]Low molecular heparin；Neonatal sepsis；Procalcitonin；C reactive protein
新生儿败血症在临床中是指细菌或真菌侵入到新生儿的血液循环，大量繁殖且形成毒素，从而使得患儿全身出现炎症反应的一种综合征。近些年来，临床中新生儿死亡率明显降低，但因感染而导致的新生儿死亡依然较多，特别对晚期新生儿死亡，其为较重要的一个不良因素[1]。新生儿败血症在临床中并无较为典型的症状，而且新生儿各个系统发育不完善，导致免疫功能较低，若未及时予以治疗，极有可能导致患儿出现其他严重并发症，导致住院时间明显延长，甚至导致严重后遗症的发生，造成潜在性的医患矛盾。因此需对患儿进行早期诊断与治疗，有效预防因新生儿败血症而死亡[2]。本文探讨低分子肝素治疗新生儿败血症治疗的有效性，现报道如下。
1资料与方法
1.1一般资料
收集我院2015年3月～2016年7月58例新生儿败血症患儿，按照入院顺序分成观察组与对照组，每组29例。对照组中，男性15例，女性14例；年龄5～26 d，平均(20.1±0.2)d。观察组中，男性16例，女性13例；年龄6～27 d，平均(19.6±0.3)d。两组患儿基础资料比较，差异无统计学意义(P>0.05)，具有可比性。 (杜佩珍 潘文中 廖沛娜)
[关键词]低分子肝素；新生儿败血症；降钙素原；C反应蛋白
[中图分类号] R722.13+1 [文献标识码] A [文章编号] 1674-4721(2017)01(c)-0098-03
[Abstract]Objective To investigate effectiveness of low molecular heparin in the treatment of neonatal sepsis.Methods 58 cases of neonatal septicemia in our hospital from March 2015 to July 2016 were collected and divided into observation group and control group according to admission order，29 cases in each group.Patients in the control group were treated by traditional antibiotic treatment，patients in the observation group were treated with low molecular heparin on the basis of the control group，clinical therapeutic effect，changes of procalcitonin (PCT) and C reactive protein (CRP) levels before and after treatment between two groups were compared.Results Total effective rate in the observation group was 96.55%，higher than 86.21% in the control group，and the difference was statistically significant (P<0.05).PCT and CRP level after treatment in the observation group was (0.29±0.17) ng/L and (5.52±2.37) mg/L respectively，significantly lower than (5.65±2.18) ng/L and (22.70±5.29 mg/L before treatment (P<0.05)；PCT and CRP level after treatment in the observation group was significantly lower than that in the control group，and the difference was statistically significant (P<0.05).Conclusion Low molecular heparin combined antibiotics in the treatment of neonatal sepsis has obvious clinical effect，can significantly improve procalcitonin and CRP level，which has high clinical value.
[Key words]Low molecular heparin；Neonatal sepsis；Procalcitonin；C reactive protein
新生儿败血症在临床中是指细菌或真菌侵入到新生儿的血液循环，大量繁殖且形成毒素，从而使得患儿全身出现炎症反应的一种综合征。近些年来，临床中新生儿死亡率明显降低，但因感染而导致的新生儿死亡依然较多，特别对晚期新生儿死亡，其为较重要的一个不良因素[1]。新生儿败血症在临床中并无较为典型的症状，而且新生儿各个系统发育不完善，导致免疫功能较低，若未及时予以治疗，极有可能导致患儿出现其他严重并发症，导致住院时间明显延长，甚至导致严重后遗症的发生，造成潜在性的医患矛盾。因此需对患儿进行早期诊断与治疗，有效预防因新生儿败血症而死亡[2]。本文探讨低分子肝素治疗新生儿败血症治疗的有效性，现报道如下。
1资料与方法
1.1一般资料
收集我院2015年3月～2016年7月58例新生儿败血症患儿，按照入院顺序分成观察组与对照组，每组29例。对照组中，男性15例，女性14例；年龄5～26 d，平均(20.1±0.2)d。观察组中，男性16例，女性13例；年龄6～27 d，平均(19.6±0.3)d。两组患儿基础资料比较，差异无统计学意义(P>0.05)，具有可比性。 (杜佩珍 潘文中 廖沛娜)